A Comprehensive Study on the Association between Plasma NOV/CCN3 Levels and Insulin Resistance in Childhood Obesity
Annals of Nutrition and Metabolism · 2024
DOI: 10.1159/000536433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Nutrition and Metabolism, 2024. Verfasst von Yuesheng Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, lothardan@163.com. Hauptthemen laut MEDLINE: Insulin Resistance, Nephroblastoma Overexpressed Protein, Pediatric Obesity, Body Mass Index. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Introduction
Childhood obesity is a global health problem that is associated with various metabolic complications, such as insulin resistance, type 2 diabetes, dyslipidemia, and cardiovascular diseases. The mechanisms underlying the development of insulin resistance in childhood obesity are not fully understood. Nephroblastoma overexpressed gene (NOV), also known as CCN3, is a member of the CCN family of matricellular proteins that modulate cell proliferation, differentiation, adhesion, migration, and survival. Previous studies have shown that NOV/CCN3 is involved in glucose metabolism and insulin signaling in various tissues and cell types. However, the role of NOV/CCN3 in childhood obesity and insulin resistance remains unclear.
Methods
In this study, we aimed to investigate the association between plasma NOV/CCN3 levels and insulin resistance in 58 obese and 43 non-obese children aged 6–12 years. We measured plasma NOV/CCN3 levels by enzyme-linked immunosorbent assay and assessed insulin resistance by homeostasis model assessment of insulin resistance (HOMA-IR). We also collected clinical and biochemical data, such as body mass index (BMI), waist circumference (WC), blood pressure (BP), fasting glucose (FG), fasting insulin (FI), lipid profile, and inflammatory markers.
Results
We found that plasma NOV/CCN3 levels were significantly higher in obese children than in non-obese children (p < 0.001) and positively correlated with BMI (r = 0.42, p < 0.001), WC (r = 0.38, p < 0.001), BP (r = 0.35, p < 0.001), FG (r = 0.31, p < 0.001), FI (r = 0.45, p < 0.001), HOMA-IR (r = 0.48, p < 0.001), triglycerides (r = 0.28, p < 0.001), low-density lipoprotein cholesterol (r = 0.26, p < 0.001), and C-reactive protein (CRP) (r = 0.32, p < 0.001). Multiple linear regression analysis revealed that plasma NOV/CCN3 levels were independently associated with HOMA-IR after adjusting for age, sex, BMI, WC, BP, FG, FI, lipid profile, and CRP (β = 0.36, p < 0.001).
Conclusion
These results suggest that plasma NOV/CCN3 levels are elevated in childhood obesity and are associated with insulin resistance, indicating that NOV/CCN3 may play a role in the pathogenesis of metabolic disorders in obese children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, lothardan@163.com.
- Neonatal Department, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, China.
- Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zitieren
APA
Liu, Y., Hao, L., Yin, C., Li, M., & Xiao, Y. (2024). A Comprehensive Study on the Association between Plasma NOV/CCN3 Levels and Insulin Resistance in Childhood Obesity. Annals of Nutrition and Metabolism. https://doi.org/10.1159/000536433
Vancouver
Liu Y, Hao L, Yin C, Li M, Xiao Y. A Comprehensive Study on the Association between Plasma NOV/CCN3 Levels and Insulin Resistance in Childhood Obesity. Annals of Nutrition and Metabolism. 2024. doi:10.1159/000536433
BibTeX
@article{Liu2024,
author = {Liu, Yuesheng and Hao, Lijun and Yin, Chunyan and Li, Min and Xiao, Yanfeng},
title = {A Comprehensive Study on the Association between Plasma NOV/CCN3 Levels and Insulin Resistance in Childhood Obesity},
journal = {Annals of Nutrition and Metabolism},
year = {2024},
doi = {10.1159/000536433}
}
EUVIMED